Loading organizations...
Nightstar Therapeutics develops novel, one-time gene therapies for patients afflicted with rare inherited retinal diseases. The company focuses on creating potentially curative treatments for conditions leading to blindness, often lacking existing therapeutic options. Its core products address diseases like choroideremia and X-linked retinitis pigmentosa, leveraging advanced techniques to preserve vision.
Founded in 2014, Nightstar Therapeutics emerged from research at the University of Oxford. Professor Robert MacLaren, a prominent Professor of Ophthalmology, commercialized his foundational work in gene therapies for inherited retinal dystrophies. This insight underpinned the company's establishment, aiming to translate academic discoveries into clinical solutions.
Nightstar Therapeutics primarily serves patients globally who face severe inherited retinal diseases, which typically result in progressive vision loss and blindness. The company’s mission is to deliver transformative treatments that tackle genetic root causes, enabling individuals to retain their sight and significantly enhance their quality of life.
Nightstar Therapeutics has raised $80.0M across 2 funding rounds.
Nightstar Therapeutics has raised $80.0M in total across 2 funding rounds.
Nightstar Therapeutics has raised $80.0M across 2 funding rounds. Most recently, it raised $45.0M Series C in June 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2017 | $45M Series C | — | Mott Family Capital, ALI Behbahani, OrbiMed, NEW Enterprise Associates, Redmile Group, Chris Hollowood, Wellington Management | Announced |
| Nov 1, 2015 | $35M Series B | David Mott | Mott Family Capital, ALI Behbahani, OrbiMed, Syncona | Announced |
Nightstar Therapeutics has raised $80.0M in total across 2 funding rounds.
Nightstar Therapeutics's investors include Mott Family Capital, Ali Behbahani, OrbiMed, New Enterprise Associates, Redmile Group, Chris Hollowood, Wellington Management, David Mott, Syncona.
Nightstar Therapeutics was a clinical‑stage gene‑therapy company that developed one‑time AAV‑based treatments for rare inherited retinal diseases and was acquired by Biogen in 2019 for $877 million[2][1].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
If you’d like, I can: (a) list Nightstar’s specific clinical programs and timelines with source citations, (b) summarize Syncona’s investment terms and performance from the Nightstar exit, or (c) map how Nightstar’s technologies compare to other retinal gene‑therapy players.